Boothbay Fund Management, LLC Adc Therapeutics Sa Transaction History
Boothbay Fund Management, LLC
- $3.6 Billion
- Q3 2024
A detailed history of Boothbay Fund Management, LLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Boothbay Fund Management, LLC holds 35,800 shares of ADCT stock, worth $86,636. This represents 0.03% of its overall portfolio holdings.
Number of Shares
35,800Holding current value
$86,636% of portfolio
0.03%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding ADCT
# of Institutions
80Shares Held
55.1MCall Options Held
82.7KPut Options Held
31.5K-
Redmile Group, LLC San Francisco, CA15.7MShares$37.9 Million3.23% of portfolio
-
Prosight Management, LP Dallas, TX9.64MShares$23.3 Million8.15% of portfolio
-
Orbimed Advisors LLC San Diego, CA4.53MShares$11 Million0.34% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$8.6 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.04MShares$7.36 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $188M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...